Trial reportThe Journal of nutrition2018
Anemia of Inflammation during Human Pregnancy Does Not Affect Newborn Iron Endowment.
Trial report in The Journal of nutrition, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00486863 (S. Japonicum and Pregnancy Outcomes), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT)
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- The association between maternal anemia and neonatal anemia: a systematic review and meta-analysis.BMC pregnancy and childbirth · 2024Pooled it
- The effect of iron supplementation on maternal iron deficiency anemia does not differ by baseline anemia type among Tanzanian pregnant women without severe iron deficiency anemia.European journal of nutrition · 2023Trial
- Maternal anemia type during pregnancy is associated with anemia risk among offspring during infancy.Pediatric research · 2019Trial
- [Recent advances in the management of iron deficiency and iron deficiency anemia during pregnancy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Review
- Article
- Red blood cell indices versus serum ferritin as surrogate markers of iron deficiency during pregnancy.PloS one · 2025Article
- Maternal Anemia during Pregnancy and Infant Birth Outcomes: A Prospective Cohort Study in Eastern Maharashtra, India.Current developments in nutrition · 2024Article
- Iron Homeostasis During Pregnancy: Maternal, Placental, and Fetal Regulatory Mechanisms.Annual review of nutrition · 2023Review
- Molecular Mechanisms and Pathophysiological Significance of Eryptosis.International journal of molecular sciences · 2023Review
- Iron transport across the human placenta is regulated by hepcidin.Pediatric research · 2022Article
- Claudin 14/15 play important roles in early wallerian degeneration after rat sciatic nerve injury.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2021Article
- Serum Erythroferrone During Pregnancy Is Related to Erythropoietin but Does Not Predict the Risk of Anemia.The Journal of nutrition · 2021Observational
- Article
- Hemoglobin and hepcidin have good validity and utility for diagnosing iron deficiency anemia among pregnant women.European journal of clinical nutrition · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 3 countries.
Funding
Abstract
Background: To our knowledge, no studies have addressed whether maternal anemia of inflammation (AI) affects newborn iron status, and few have addressed risk factors for specific etiologies of maternal anemia. Objectives: The study aims were to evaluate 1) the contribution of AI and iron deficiency anemia (IDA) to newborn iron endowment, 2) hepcidin as a biomarker to distinguish AI from IDA among pregnant women, and 3) risk factors for specific etiologies of maternal anemia. Methods: We measured hematologic biomarkers in maternal blood at 12 and 32 wk of gestation and in cord blood from a randomized trial of praziquantel in 358 pregnant women with Schistosoma japonicum in The Philippines. IDA was defined as anemia with serum ferritin <30 ng/mL and non-IDA (NIDA), largely due to AI, as anemia with ferritin ≥30 ng/mL. We identified cutoffs for biomarkers to distinguish IDA from NIDA by using area under the curve (AUC) analyses and examined the impact of different causes of anemia on newborn iron status (primary outcome) by using multivariate regression modeling. Results: Of the 358 mothers, 38% (n = 136) had IDA and 9% (n = 32) had NIDA at 32 wk of gestation. At 32 wk of gestation, serum hepcidin performed better than soluble transferrin receptor (sTfR) in identifying women with NIDA compared with the rest of the cohort (AUCs: 0.75 and 0.70, respectively) and in identifying women with NIDA among women with anemia (0.73 and 0.72, respectively). The cutoff that optimally distinguished women with NIDA from women with IDA in our cohort was 6.1 µg/L. Maternal IDA, but not NIDA, was associated with significantly lower newborn ferritin (114.4 ng/mL compared with 148.4 µg/L; P = 0.042). Conclusions: Hepcidin performed better than sTfR in identifying pregnant women with NIDA, but its cost may limit its use. Maternal IDA, but not NIDA, is associated with decreased newborn iron stores, emphasizing the need to identify this cause and provide iron therapy. This trial was registered at www.clinicaltrials.gov as NCT00486863.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.